Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III
Company Pauses OV101 Program Based On NEPTUNE Results
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.
You may also be interested in...
Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.
2020 has kicked off with a major European biotech deal that will see the Italian conglomerate Angelini take over Switzerland's Arvelle which is on the verge of getting EU approval for an anti-epilepsy drug licensed from SK Bio that got the green light in the US two years ago.